Network Ad
💫 Pop Pulse — Celebrity gossip & entertainment Explore
Loading...
Happy 85% Chaos 20% Sad 5% Well 90% Anger 10% Fear 15% Surprise 30%
» Neuroscience » Permalink » Source
0

VectorY Therapeutics and Shape Therapeutics have entered an option and license agreement to advance vectorized antibody therapies for neurodegenerative diseases, according to the company. The deal grants VectorY exclusive rights to evaluate Shape’s SHP-DB1, a deep-brain-penetrating AAV5-derived capsid, for vectorized antibodies targeting three therapeutic areas. Upon successful evaluation, VectorY may obtain an exclusive license for […] The post VectorY therapeutics licenses Shape AAV5 capsid for neurodegenerative treatments appeared first on Longevity.Technology.

(0) Comments 0 💬
More in Neuroscience →
Be respectful and constructive. Comments are moderated.

No comments yet.